Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Saw Palmetto and Improved Maximum Urinary Flow Rate

Doses used in studies

mg/day: 320–960 (median 560, IQR 400–800) — 2 studies

Time to effect

Median: 182.5 months · IQR 182.5 months–182.5 months · Range 182.5 months–182.5 months — Reported in 1 of 2 studies

Safety in these studies

adverse eventsNo significant difference
Adverse events of Serenoa repens extracts were few and mild, and incidences were not statistically significantly different vs placebo.
from: Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane sys
Overall tolerabilityReported
the patients had no adverse events related to the study drug, including prostate cancer
from: 15 years' survey of safety and efficacy of Serenoa repens extract in benign prostatic hype
Overall tolerabilityReported
Adverse events were generally mild and comparable to placebo.
from: Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane sys

2 of 2 papers

Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
- 2012-05-02
- Systematic Review · n = 2,008
- BJU international 109(12)
- - Roderick MacDonald
  - James W Tacklind
  - Indulis Rutks
  - Timothy J Wilt
- PubMed: 22551330
- DOI: 10.1111/j.1464-410x.2012.11172.x
4 Insights on
- Improved Maximum Urinary Flow Rate
- High evidence
- Clinical
Q(max) measured at study endpoint were also not significantly different between treatment groups (WMD 1.15 mL/s, 95% CI -0.23 to 2.53)
Effect
Neutral
Effect size
Small
Significant
No
Dose
320 mg/day
15 years' survey of safety and efficacy of Serenoa repens extract in benign prostatic hyperplasia patients with risk of progression.
- 2018-05-09
- Observational · n = 30
- Urologia 86(1)
- - Andrey Zinovievich Vinarov
  - Leonid Grigorievich Spivak
  - Darina Vladimirovna Platonova
  - Leonid Mikhailovich Rapoport
  - Dmitry Olegovich Korolev
- PubMed: 29741118
- DOI: 10.1177/0391560318772466
6 Insights on
- Improved Maximum Urinary Flow Rate
- Moderate evidence
- Clinical
The study showed an absence of progression based on both subjective (the sum of scores on the IPSS and QoL scales) and objective (prostate volume, urination rate, residual urine volume) criteria.
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
320 mg once a day